Can tailored drugs after surgery keep melanoma from coming back?

NCT ID NCT04741997

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether giving different drug combinations after surgery, based on how well the tumor responded to initial treatment, can reduce the risk of melanoma returning. About 50 adults with stage III or IV BRAF-mutant melanoma will receive encorafenib, binimetinib, and/or nivolumab. The goal is to see if this personalized approach improves relapse-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: encorafenib, binimetinib, and nivolumab
What this could lead to: If successful, this could lead to a more personalized treatment plan that lowers the chance of melanoma returning after surgery.
What could go wrong: This is a very early, small pilot study (50 people), so results may not apply broadly. The drugs can cause side effects like nausea, fatigue, or more serious reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAF V600 MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAF V600 MUTATION MELANOMA STAGE III MELANOMA STAGE IV

Contacts and locations

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.